Medications such as corticosteroids and proton pump inhibitors have shown the potential to improve the symptoms of EGID, reduce the number of eosinophils in the esophagus, and decrease inflammation. Persistent esophageal inflammation, however, can lead to serious complications such as strictures. Considered a rare disease only 10-20 years ago, EGID is now commonly encountered in clinical practice. Despite this increasing prevalence, there are currently no approved therapies in the US for treating EGID. A lack of validated outcome instruments has contributed to this unmet need.
Systematically review the operating properties of EGID outcome measures
Standardize histopathologic scoring conventions
Improve the reliability of histopathologic assessment
Assess the operating properties of endoscopic outcomes
Recommend appropriate outcome measures for clinical trials
Experience spanning more than 30 years in the design and conduct of early to late-phase multi-center global clinical trials
Collaboration with internationally recognized EGID experts
Participation in a global initiative for the development of an EGID clinical trial core outcome set
A vast global network of gastroenterology investigators and their EGID patient population
Central histopathology and endoscopy image management solutions for image capture and assessment by central reviewers
Highly trained central endoscopy and histopathology readers whose disease-specific expertise can reduce histopathologic and endoscopic outcome variability
Scientific collaborators and strategic scientific partnerships that facilitate the design and operationalization of translational medicine research (e.g., immunohistochemistry) in clinical trials
Biostatisticians whose expertise in clinical trials ensures high-quality and clinically relevant results
Back
